Remedica
Vijay Zutshi has diverse work experience in the pharmaceutical and healthcare industries. Vijay is currently serving as the Chief Commercial Officer (CCO) at Remedica since July 2022. Previously, they worked at Sandoz from 2013 to 2022, where they held multiple roles including Cluster Head, Head of Strategy Planning & BI, Head of Business Development & Strategy, and Associate Director of Strategy Planning & Growth Initiatives. Before that, they worked at Novartis as an Associate Director of Business Analytics from 2010 to 2013. Vijay also has experience as an Associate Director at Synovate Healthcare from 2008 to 2010, as a Sr. Manager at IMS Health from 2007 to 2008, and as a Marketing Manager at Vascular Concepts Ltd from 2004 to 2007. Before that, they started their career at Astra Zeneca as a Territory Business Manager in 2004.
Vijay Zutshi has a diverse education history, starting with a Bachelor's degree in Microbiology from Pandit Ravishankar Shukla University in 1995. Vijay went on to obtain a Master's degree from the Indian Institute of Foreign Trade between 2005 and 2007. In 2011, they completed an Executive Program in Strategic Thinking from the Indian School of Business. Later in 2013, they attended The Wharton School for the Lead Global Project Program in Project Management. Additionally, Vijay has obtained certifications in areas such as Communicating with Diplomacy and Tact, Developing Executive Presence, and Navigating Politics as a Senior Leader from LinkedIn in 2020.
This person is not in any offices
Remedica
Remedica, is a leading pharmaceutical company, with export activities in more than 160 countries. Originally founded in 1960 by Mr. Takis Pattichis, Remedica specialises in the development, production and sale of high-quality, safe and efficacious pharmaceutical products for human use. Furthermore, Remedica offers out-licensing opportunities and its product portfolio consists of Antineoplastic agents, Antivirals, Aromatase inhibitors, Antiinfectives, products for the nervous system, products for the cardiovascular system, dermatologicals, antimalarials, and has pipeline consisting of more Therapeutic Categories. Currently, Remedica has 5 state-of-the-art factories all of which have been routinely inspected and approved by the health authorities of several European Union Member States including Cyprus, Germany, and Denmark as well as those of United Kingdom, Russia, Australia (TGA), Brazil (ANVISA), Japan (PMDA) and many more. Remedica invests in product development, in innovation and technology, and in human resources, and encourages the progress of science, education and health. Remedica’s Corporate Social Responsibility (CSR) commitment is built on its vision, strategies and mission. It is based on its core business, operating background, stakeholder’s outlooks and company’s culture. By providing safe, efficacious and high quality pharmaceuticals at affordable prices, Remedica has improved the health and saved the lives of millions of people who may otherwise have had to pay more or who may not have been in a position to afford a more expensive treatment. To meet this commitment the company implements management systems in its operations that accord with the requirements of its CSR standards. Remedica’s CSR is based on various parameters which include but are not limited to Environment, Human Resources, Society and Education.